Organogenesis Holdings INC. (ORGO) — SEC Filings

Overview

Organogenesis Holdings INC. (ORGO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Organogenesis Holdings Inc. filed an 8-K on December 29, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The filing date for the report is December 22, 2025. The company, previously known as Avista Healthcare Public Acquisition Corp., is incorporated

Sentiment Summary

Across 25 filings, the sentiment breakdown is: 1 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Organogenesis Holdings INC. is neutral.

Filing Type Overview

Organogenesis Holdings INC. (ORGO) has filed 9 8-K, 6 10-Q, 2 DEF 14A, 1 10-K/A, 2 10-K, 1 SC 13D, 2 SC 13G/A, 1 SC 13D/A, 1 SC 13G with the SEC between Feb 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (25)

• Organogenesis Holdings Inc. Files 8-K — 8-K · Dec 29, 2025 Risk: low
  Organogenesis Holdings Inc. filed an 8-K on December 29, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The fi
• ORGO's Q3 Net Income Soars 75% on Strong Product Revenue — 10-Q · Nov 6, 2025 Risk: medium
  Organogenesis Holdings Inc. (ORGO) reported a significant increase in net income for the three months ended September 30, 2025, reaching $21.567 million, up fro
• Organogenesis Holdings Inc. Files 8-K — 8-K · Sep 25, 2025 Risk: low
  Organogenesis Holdings Inc. filed an 8-K on September 25, 2025, reporting on various events. The filing includes information related to Regulation FD disclosure
• Organogenesis Q2 Revenue Plunges 15%, Swings to $10.5M Loss — 10-Q · Aug 7, 2025 Risk: high
  Organogenesis Holdings Inc. reported a significant decline in revenue and net income for the second quarter ended June 30, 2025. Total net revenue decreased by
• Organogenesis Holdings Inc. Announces Board and Executive Changes — 8-K · Jun 24, 2025 Risk: medium
  Organogenesis Holdings Inc. announced on June 23, 2025, changes related to its board of directors and executive compensation. The filing indicates a departure o
• Organogenesis Holdings Inc. DEF 14A: Executive Compensation Details — DEF 14A · May 12, 2025 Risk: medium
  Organogenesis Holdings Inc. filed a DEF 14A on May 12, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation, including
• Organogenesis Holdings Inc. Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Organogenesis Holdings Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations. Key
• Organogenesis Holdings Inc. Files 10-K/A Amendment — 10-K/A · Apr 29, 2025 Risk: low
  Organogenesis Holdings Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, previously known as Avist
• 8-K Filing — 8-K · Mar 27, 2025
• Organogenesis Holdings Inc. Files 2024 10-K — 10-K · Feb 27, 2025 Risk: medium
  Organogenesis Holdings Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly Avista Health
• Organogenesis Holdings Inc. Files 8-K for Material Agreement — 8-K · Dec 2, 2024 Risk: medium
  Organogenesis Holdings Inc. entered into a Material Definitive Agreement on November 27, 2024. The filing also includes financial statements and exhibits. The c
• Organogenesis Holdings Inc. Files 8-K for Material Definitive Agreement — 8-K · Nov 22, 2024 Risk: medium
  Organogenesis Holdings Inc. announced on November 18, 2024, that it entered into a Material Definitive Agreement. The company, formerly known as Avista Healthca
• Avista Healthcare Partners III Files SC 13D for Organogenesis Holdings — SC 13D · Nov 19, 2024 Risk: medium
  Avista Healthcare Partners III, L.P. and its affiliates, including AHP III ORCHESTRA HOLDINGS, L.P., AVISTA CAPITAL MANAGING MEMBER VI, LLC, AVISTA CAPITAL PART
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Ades Group Amends Organogenesis Holdings Stake Filing — SC 13D/A · Nov 14, 2024 Risk: medium
  On November 14, 2024, Alan A. Ades and related entities filed an amendment (No. 7) to their Schedule 13D concerning Organogenesis Holdings Inc. The filing indic
• Organogenesis Holdings Inc. Files 8-K with Material Agreements and Officer Changes — 8-K · Nov 13, 2024 Risk: medium
  Organogenesis Holdings Inc. announced on November 12, 2024, that it entered into a material definitive agreement. The company also reported on triggering events
• Organogenesis Holdings Inc. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
  Organogenesis Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business
• Organogenesis Holdings Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 8, 2024 Risk: low
  Organogenesis Holdings Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly Avista Healthcare Public Acquisition Corp., is incorporate
• Organogenesis Names New CEO and CFO — 8-K · Jun 21, 2024 Risk: medium
  Organogenesis Holdings Inc. announced on June 20, 2024, that its Board of Directors has appointed Dr. Marc H. Miller as Chief Executive Officer, effective immed
• Organogenesis Holdings Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  Organogenesis Holdings Inc. (ORGO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Organogenesis Holdings Inc. filed a 10-Q report for the period e
• Organogenesis Holdings Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  Organogenesis Holdings Inc. (ORGO) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Organogenesis Holdings Inc. filed a Definitive Proxy Statem
• Organogenesis Sells Trauma Business to Acellixx — 8-K · Apr 3, 2024 Risk: medium
  Organogenesis Holdings Inc. announced on April 3, 2024, that it has entered into a definitive agreement to sell its Trauma business to Acellixx, Inc. for an und
• Organogenesis Holdings Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Organogenesis Holdings Inc. (ORGO) filed a Annual Report (10-K) with the SEC on February 29, 2024. Organogenesis Holdings Inc. filed its 2023 Form 10-K on Febru
• Morgan Stanley Discloses Passive Stake in Organogenesis Holdings — SC 13G · Feb 9, 2024 Risk: low
  Morgan Stanley, a major financial institution, reported its holdings in Organogenesis Holdings Inc. (ORGO) as of December 31, 2023, through an SC 13G filing. Th
• Soleus Capital Amends Organogenesis Holdings Stake — SC 13G/A · Feb 2, 2024
  Soleus Capital Master Fund, L.P. filed an amended Schedule 13G/A on February 2, 2024, indicating a change in their beneficial ownership of Organogenesis Holding

Risk Profile

Risk Assessment: Of ORGO's 22 recent filings, 1 were flagged as high-risk, 15 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Organogenesis Holdings INC.'s most recent 10-Q filing (Nov 6, 2025):

• Revenue: $338.562M
• Net Income: ($6.668M)
• EPS: N/A
• Debt-to-Equity: 0.485
• Cash Position: $63.745M
• Operating Margin: N/A
• Total Assets: $509.827M
• Total Debt: $123.848M

Key Executives

• David Burgstahler
• Thompson Dean
• Alan A. Ades
• ALBERT ERANI
• DENNIS ERANI
• GLENN H. NUSSDORF
• Dr. Marc H. Miller
• Jennifer K. Chagnon
• Richard L. Thompson

Industry Context

Organogenesis operates in the regenerative medicine and advanced wound care market, a sector characterized by innovation, significant R&D investment, and evolving regulatory landscapes. The industry is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Key trends include the development of cell-based therapies, biomaterials, and digital health solutions for patient monitoring and treatment.

Top Tags

financials (4) · 10-Q (4) · material-agreement (3) · corporate-governance (3) · healthcare (3) · Organogenesis Holdings (3) · executive-compensation (2) · amendment (2) · annual-report (2) · 10-K (2)

Key Numbers

• Commission File Number: 001-37906 — SEC File Number for Organogenesis Holdings Inc.
• IRS Employer Identification No.: 98-1329150 — Tax Identification Number for Organogenesis Holdings Inc.
• Net Product Revenue: $150.487M — Increased from $115.177M in Q3 2024, a 30.66% increase.
• Net Income (Q3 2025): $21.567M — Increased from $12.331M in Q3 2024, a 74.9% increase.
• Net Loss (YTD Sep 2025): ($6.668M) — Improved from ($6.812M) in YTD Sep 2024.
• Cash and Cash Equivalents: $63.745M — Decreased from $135.571M at Dec 31, 2024, a 52.99% decrease.
• Net Cash Used in Operating Activities: ($49.729M) — For the nine months ended September 30, 2025, compared to $3.271M provided in 2024.
• Write-down for asset held for sale: $9.235M — Operating expense for the nine months ended September 30, 2025.
• Class A Common Stock Outstanding: 126,912,142 — As of October 30, 2025.
• SEC File Number: 001-37906 — Identifies the company's filing with the SEC.
• Total Net Revenue: $95.0M — Decreased by 15.0% from $111.8M in Q2 2024
• Net Income (Loss): -$10.5M — Swung from a $5.2M net income in Q2 2024 to a net loss
• Diluted EPS: -$0.08 — Compared to $0.04 EPS in Q2 2024
• Gross Margin: 68.4% — Contracted from 70.5% in Q2 2024
• Advanced Wound Care Revenue: $87.0M — Decreased by 15.5% from prior year

Forward-Looking Statements

• {"claim":"Morgan Stanley will maintain a passive investment in Organogenesis Holdings Inc. for the foreseeable future.","entity":"Morgan Stanley","targetDate":"2025-12-31","confidence":"high"}

Related Companies

ORG · OGSN

Frequently Asked Questions